You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK):JS009注射液獲得藥物臨牀試驗申請受理通知書
格隆匯 12-03 19:26

格隆匯12月3日丨君實生物(01877.HK)發佈公吿,近日,公司收到國家藥品監督管理局核准簽發的《受理通知書》,JS009注射液的臨牀試驗申請獲得受理。

JS009是公司獨立自主研發的重組人源化抗CD112R單克隆抗體注射液,主要用於晚期惡性腫瘤的治療。CD112R又名PVRIG(脊髓灰質炎病毒受體相關免疫球蛋白結構域),是PVR家族的一個單跨膜蛋白,主要表達於T細胞和NK細胞上,並在細胞激活後有明顯的表達上調。CD112R與抗原遞呈細胞和部分腫瘤細胞表面的CD112具有高親和力,結合後可抑制T細胞和NK細胞的抗腫瘤作用。

JS009能以高親和力特異性地結合CD112R,有效阻斷CD112R與其配體CD112信號通路,進而促進T細胞和NK細胞的活化和增殖,增強免疫系統殺傷腫瘤細胞的能力。同時JS009選擇了IgG4亞型,可降低抗體依賴的細胞介導的細胞毒性作用(ADCC)和補體依賴的細胞毒性(CDC)。JS009是國內首個獲得藥物臨牀試驗申請受理的抗CD112R單克隆抗體注射液。截至本公吿披露日,國內外尚無同類靶點產品獲批上市。

TIGIT是PVR家族的另一個免疫抑制靶點,其配體有PVR和CD112,且其結合CD112的位點不同於CD112R。臨牀前體內藥效實驗顯示,JS009與公司自主研發的特異性抗TIGIT單克隆抗體注射液(項目代號“JS006”)聯合治療,表現出顯着的協同抗腫瘤作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account